Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 255-261

  Tham, Lai San ^a   Lee, How Sung ^b   Wang, Lingzhi ^a,b   Yong, Wei Peng ^a   Fan, Lu ^b   Ong, Ai Bee ^a   Sukri, Norita ^a   Soo, Ross ^a   Lee, Soo Chin ^a   Goh, Boon Cher ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CYP3A; Ketoconazole; Limited sampling strategy; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; KETOCONAZOLE; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; FEMALE; HUMAN; HYPOTHESIS; LUNG CANCER; MALE; MESOTHELIOMA; MODEL; MOLECULAR PROBE; NASOPHARYNX CANCER; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SAMPLING; STOMACH CANCER;

ADMINISTRATION, ORAL; ANESTHETICS, INTRAVENOUS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; ISOENZYMES; KETOCONAZOLE; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; TAXOIDS;

EID: 33748181541     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000194497.55269.d9     Document Type: Article

References (38)

1. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413-580.
2. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995;29:619-624.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
4. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66:461-471.
5. Yu KS, Cho JY, Jang IJ, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004;76:104-112.
6. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther. 1994;271:549-556.
7. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther. 1994;271:557-566.
8. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001;11:781-791.
9. Lee HS, Goh BC, Fan L, et al. Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. Br J Clin Pharmacol. 2003;55:270-277.
10. Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004;96:1585-1592.
11. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20:3683-3690.
12. Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther. 1999;65:630-639.
13. Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr. 1995;61 (3 Suppl):651S-658S.
14. Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res. 1998;400:201-213.
15. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 1996;31:47-64.
16. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004;26:192-199.
17. Toyo'oka T, Kumaki Y, Kanbori M, et al. Determination of hypnotic benzodiazepines (alprazolam, estazolam, and midazolam) and their metabolites in rat hair and plasma by reversed-phase liquid-chromatography with electrospray ionization mass spectrometry. J Pharm Biomed Anal. 2003;30:1773-1787.
18. Chen YL, Felder L, Jiang X, et al. Determination of ketoconazole in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;774:67-78.
19. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
20. Wu G. Calculating predictive performance: a user's note. Pharmacol Res. 1995;31:393-399.
21. Terwogt JM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999;5:3379-3384.
22. Malingre MM, Ten Bokkel Huinink WW, Duchin K, et al. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. Anticancer Drugs. 2001;12:591-593.
23. Malingre MM, Ten Bokkel Huinink WW, Mackay M, et al. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol. 2001;57:305-307.
24. Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol. 2001;19:1160-1166.
25. Guo XD, Harold N, Saif MW, et al. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol. 2003;52:79-85.
26. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55:481-485.
27. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998; 64:133-143.
28. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511-516.
29. von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol. 1996;36:783-791.
30. Gibbs MA, Thummel KE, Shen DD, et al. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos. 1999;27:180-187.
31. Bourrie M, Meunier V, Berger Y, et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther. 1996;277:321-332.
32. Mandema JW, Tukker E, Danhof M. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol. 1991;102:663-668.
33. Villeneuve JP, L'Ecuyer L, De Maeght S, et al. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. Clin Pharmacol Ther. 2000;67:242-248.
34. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59:491-502.
35. Kinirons MT, O'Shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther. 1999;66:224-231.
36. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002;42:376-382.
37. Zimmerman CL, Slattery JT. Maintenance-dose prediction based on a single determination of concentration: general applicability to two-compartment drugs with reference to lithium. J Pharm Sci. 1983;72:1262-1266.
38. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetics/ Pharmacodynamics Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 1997.